|Articles|September 28, 2009

Researchers Discover a New Antibacterial Compound

Antibiotic resistance has been a significant problem for hospitals and healthcare facilities for more than a decade. But despite the need for new treatment options, there have been only two new classes of antibiotics developed in the last 40 years.

Now a promising discovery by McMaster University researchers has revealed an ideal starting point to develop new interventions for resistant infections.

Eric Brown, a professor and chair of the Department of Biochemistry and Biomedical Sciences, and a team of researchers from the Michael G. DeGroote Institute for Infectious Disease Research have identified a novel chemical compound that targets drug-resistant bacteria in a different way from existing antibiotics. The discovery could lead to new treatments to overcome antibiotic resistance in certain types of microorganisms.

The findings were published Sept. 27 in the science research journal Nature Chemical Biology.

"Everyone reads the headlines about drug-resistant bugs, it's a big problem," said Brown, who holds the Canada Research Chair in Antimicrobial Research. "Really what we're trying to do is understand whether or not there are new ways to tackle this problem."

The research team, which included biochemists and chemists from McMaster University, used high-throughput screening to uncover the new class of chemical. The approach allows scientists to look for small molecules that kill bacteria as well as examine the molecular mechanisms and pathways they exploit.

Existing antibiotics destroy bacteria by blocking production of its cell wall, DNA or protein. The new McMaster-discovered compound, MAC13243, is directed at blocking a particular step in the development of the bacteria's cell surface, which until now has not been recognized as a target for antibiotics.

"We're excited about finding a new probe of a relatively uncharted part of bacterial physiology," Brown said. "It's a new way of thinking about the problem. Who knows, could this chemical become a drug? Anything's possible. But at the very least we've advanced the field and created some tools that people can use now to try to better understand this pathway."

Ranjana Pathania, a former postdoctoral fellow in the Brown lab and now an assistant professor at the Indian Institute of Technology Roorkee, is the lead author of the study. The research also involved collaborators in McMaster's Department of Biochemistry and Biomedical Sciences and Department of Chemistry and Chemical Biology.


Related to this article

Water  (Adobe Stock 456102510 by stockphoto-graf)
Understanding current water quality is a starting point for ST108 implementation. John Kimsey, vice president of processing optimization and customer success for STERISS, spoke about his HSPA presentation on assessing readiness, distinguishing system qualification from routine testing, and understanding where water samples should be collected.
Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
AORN26 New Orleans 2026  (Adobe Stock)
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.